A clinical trial to study the effect of wet cupping in comparison to Diclofenac gel in patients with knee osteoarthritis

Therapeutic Evaluation of Hijamat-bish-Shart (Wet Cupping) in the treatment of Knee Osteoarthritis. - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/12/010901

Enrollment

Registered

2017-12-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M170- Bilateral primary osteoarthritis of knee Health Condition 2: M170- Bilateral primary osteoarthritis of knee Health Condition 3: null- knee osteoarthritis

Interventions

Intervention1: To evaluate the safety and efficacy of Hijamat-bish-shart (Wet Cupping) in the treatment of knee osteoarthritis.: Randomized control trial intervention: Hijamat-bish-shart (Wet Cupping)

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed according to American College of Rheumatology Criteria for Osteoarthritis. 2. Patients with symptoms consistent with OA of knee for at least six months prior to screening. 3. Patients who discontinued all NSAIDS or other analgesic medication taken for any other condition, including their knee pain. 4. Patients signed the informed consent and follow the protocol voluntarily

Exclusion criteria

Exclusion criteria: 1. Pregnancy and lactation 2. Anemia 3. Uncontrolled Diabetes Mellitus 4. Patients taking anticoagulants 5. Patients with a past history of blood disorders 6. Patients participated in an experimental device, study or any clinical trial within the previous 30 days prior to screening 7. Any knee surgery in the previous three months 8. Other types of arthritis 9. Patients with any inter current disease(s) or condition(s) that may interfere with the completion of six week follow upâ??neurological problems, severe congenital defects, peptic ulcer, severe liver disease, severe coronary disease, hypertension, renal disease, abnormal mental state, or other clinically significant conditions 10. Patients on steroid therapy or NSAIDS. 11. Patients unable to understand WOMAC questionnaire form. 12. Patients allergic to topical diclofenac gel and with a history of gastritis.

Design outcomes

Primary

Measure	Time frame
WOMAC (Western Ontario and McMaster Universities Osteoarthritis) Index. Active range of motion. Radiological assessment (Kellgren-Lawrence Radiographic Grading Scale of Osteoarthritis of the Tibiofemoral Joint, all Grades) Visual analogue scale (VAS)Timepoint: The assessments of efficacy was made at day 28 and 42 (for WOMAC Index, Active Range of Motion and VAS. Laboratory and radiological assessment WAS made only at day 42.	—

Measure

Time frame

WOMAC (Western Ontario and McMaster Universities Osteoarthritis) Index. Active range of motion. Radiological assessment (Kellgren-Lawrence Radiographic Grading Scale of Osteoarthritis of the Tibiofemoral Joint, all Grades) Visual analogue scale (VAS)Timepoint: The assessments of efficacy was made at day 28 and 42 (for WOMAC Index, Active Range of Motion and VAS. Laboratory and radiological assessment WAS made only at day 42.

—

Secondary

Measure	Time frame
To provide safe alternative and economical treatment for knee osteoarthritisTimepoint: To provide safe alternative and economical treatment for knee osteoarthritis	—

Countries

India

Contacts

Public ContactDr Fasihuzaman

jamia hamdard

jabeendr@gmail.com9899315252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026